June 30 – July 1, 2023 – Loews Portofino Bay Hotel – Orlando, Florida
This course provides attendees with relevant information regarding new developments in hepatology, and novel approaches to the management of liver diseases that can be readily integrated into daily clinical practice. Nationally and internationally renowned experts present new findings in a case-based format that highlights the management of common, as well as unique and complex liver diseases and liver cancers.
More information: https://ce.mayo.edu/hepatology2023
Program at Glance:
- Predicting and preventing hepatic decompensation
- Sarcopenia and frailty in cirrhosis
- Evaluation and management of kidney disease in cirrhosis
- Thrombosis and bleeding in cirrhosis
- Genetics in liver disease
- The pediatric patient with liver disease grows up: What now?
- Screening, diagnosing, and preventing HCC
- Surgery, liver transplantation, systemic and locoregional therapies for HCC
- Current management of acute liver failure
- Optimal management of acute alcoholic hepatitis
- Evaluation and management of acute autoimmune hepatitis
- NAFLD — biomarkers and screening and treatment
- Medical management of obesity
- Bariatric surgery and endoscopic therapies for obesity
- State-of-the-art talk: Ex vivo liver machine perfusion — opening doors and improving outcomes
- Systemic therapies for HCC
Upon completion of this activity, participants should be able to:
- Review contemporary and emerging approaches to managing patients with advanced liver disease and acute liver failure.
- Identify emerging trends and treatments in cholestatic, autoimmune and fatty liver disease.
- Review genetic liver diseases, focusing on the latest practice guidelines and management.
- Examine emerging areas of new innovations in managing patients with liver diseases and in need of organ support.
- Assess the current development and treatment of liver cancer, encompassing all medical, surgical and transplant options.
- Determine the latest concepts in management options in cholestatic, autoimmune and fatty liver disease